Background: Either dual antiplatelet therapy or oral anticoagulation in combination with aspirin represent recommended treatment regimens following left atrial appendage closure (LAAC). As the majority of patients receiving LAAC have high bleeding risk, less aggressive antithrombotic treatments are needed, such as single antiplatelet therapy.
Objectives: To compare both ischemic and bleeding outcomes in patients receiving single (SAPT) or dual antiplatelet therapy (DAPT) after successful LAAC.
Methods: Data on consecutive patients undergoing percutaneous LAAC between 2009 and 2023 were prospectively collected including one-year follow-up. A propensity score matching was performed among patients discharged under SAPT and DAPT. The primary endpoint was the one-year composite of cardiovascular death, stroke, systemic embolism or device related thrombosis (DRT). The secondary endpoints included major bleeding and DRT.
Results: Among 1033 patients discharged with antiplatelet therapy, 154 patients receiving SAPT were compared to 230 matched patients receiving DAPT. The primary endpoint was similar between the two study groups (SAPT 11.0% vs. DAPT 8.3%; Rate Ratio [RR]: 1.14; 95% Confidence Interval [CI]: 0.83-1.55; p=0.420). Consistently, we found no difference in terms of both major bleedings (SAPT 9.7% vs. DAPT 12.6%; Hazard Ratio: [HR]: 0.77; 95% CI: 0.43-1.39; p=0.387) and DRT (2.6% vs. 1.1%; RR:1.47; 95% CI: 0.89-2.43; p=0.130) between SAPT and DAPT groups.
Conclusions: In this propensity score analysis of a single-center LAAC cohort, both ischemic and bleeding outcomes did not differ at 1 year between patients discharged with SAPT or DAPT. These results have to be confirmed in an adequately powered randomized clinical trial.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hrthm.2024.12.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of different antiplatelet therapy drugs on platelet activation and platelet-leukocyte aggregate formation in early septic ARDS.
BMC Pharmacol Toxicol
January 2025
Department of Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100730, China.
Background: In patients with sepsis, platelets are activated and adhere to neutrophils, forming platelet-leukocyte aggregates (PLAs) that lead to the development of MODS. ARDS is one of the main manifestations of septic MODS. We designed this study to explore the effects of different anti-plate therapy drugs on platelet activation and platelet-leukocyte aggregate (PLA) formation in the early stage of septic ARDS.
View Article and Find Full Text PDFInappropriate antithrombotic use in geriatric patients with complicated traumatic brain injury.
J Trauma Acute Care Surg
January 2025
From the Spencer Fox Eccles School of Medicine (D.G., J.A.), Department of Neurosurgery (D.B., M.T.B., S.T.M., R.G.), Department of Surgery (S.L., J.C., M.M., T.E.), Division of Geriatrics and Department of Internal Medicine (M.P.), University of Utah, Salt Lake City, Utah; and Bowers Neurosurgical Frailty and Outcomes Data Science Lab (C.A.B.), Flint, Michigan.
Background: Preinjury antithrombotic (AT) use is associated with worse outcomes for geriatric (65 years or older) patients with traumatic brain injury (TBI). Previous studies have found that use of AT outside established guidelines is widespread in TBI patients.
Methods: In this single-center retrospective cross-sectional study, we examined inappropriate AT use among geriatric patients presenting with traumatic intracranial hemorrhage.
Cangrelor Use for Viabahn Stent Graft Patency as Bridge to Coronary Artery Bypass Graft Surgery.
J Pharm Pract
January 2025
Department of Cardiothoracic Surgery, Jefferson Health Abington Hospital, Abington, PA, USA.
Utilization of cangrelor following coronary artery stent placement as a bridge to cardiac surgery has been previously described in the literature. However, the use of cangrelor as bridge therapy to cardiac surgery for endovascular revascularization is lacking. We describe a case involving a 47-year-old female who developed a left lower extremity tibioperoneal trunk non-obstructing arterial dissection following extracorporeal membrane oxygenation decannulation, requiring repair with a Viabahn endoprosthesis.
View Article and Find Full Text PDFReal-world antithrombotic strategies in patients with atrial fibrillation and recently developed acute coronary syndrome.
Int J Cardiol Cardiovasc Risk Prev
March 2025
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Background: The antithrombotic strategy for patients with atrial fibrillation (AF) and coronary artery disease following percutaneous coronary intervention is shifting towards less intensive. Nevertheless, for patients with AF and acute coronary syndrome (ACS), an optimal antithrombotic strategy is yet to be established.
Methods And Results: We conducted a multi-center cohort study involving 146 Japanese centers that had prospectively registered 460 patients with AF and ACS followed for 2 years.
Effect of intravenous urokinase vs best medicine treatment on functional outcome for patients with acute minor stroke (TRUST): a randomized controlled trial.
BMC Med
January 2025
Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Background: The benefits of intravenous thrombolysis in patients with acute minor stroke remain controversial. For the aim of providing a better therapeutic strategy, high-quality trials are required to validate the efficacy of thrombolytic medicine other than intravenous recombinant tissue plasminogen and tenecteplase. In the trial, we evaluate the efficacy and safety of urokinase (UK) in acute minor stroke.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!